The promise of integrins as effective targets for anticancer agents

Journal of Biomedicine and Biotechnology

Volumn 2, Issue 3, 2003, Pages 124-130

  Rust, William L ^a,c   Carper, Stephen W ^a   Plopper, George E ^b  

^a UNIVERSITY OF NEVADA   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; INTEGRIN; MONOCLONAL ANTIBODY; POLYPEPTIDE; TAMOXIFEN;

APOPTOSIS; CANCER; CANCER GROWTH; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL SURFACE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; GENE THERAPY; HUMAN; METASTASIS; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ADENOVIRIDAE;

EID: 0345454812     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724302204015     Document Type: Review

References (52)

1. Engers R, Gabbert HE. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol. 2000;126(12):682-692.
2. Berman AE, Kozlova NI. Integrins: structure and functions. Membr Cell Biol. 2000;13(2):207-244.
3. Parise LV, Lee J, Juliano RL. New aspects of integrin signaling in cancer. Semin Cancer Biol. 2000;10(6):407-414.
4. Zhao JH, Guan JL. Role of focal adhesion kinase in signaling by the extracellular matrix. Prog Mol Subcell Biol. 2000;25:37-55.
5. Mercurio AM, Bachelder RE, Rabinovitz I, O'Connor KL, Tani T, Shaw LM. The metastatic odyssey: the integrin connection. Surg Oncol Clin N Am. 2001;10(2):313-328.
6. Coppolino MG, Dedhar S. Bi-directional signal transduction by integrin receptors. Int J Biochem Cell Biol. 2000;32(2):171-188.
7. Ivaska J, Heino J. Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell Mol Life Sci. 2000;57(1):16-24.
8. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000;19(49):5606-5613.
9. Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol. 2000;2(12):E231-E236.
10. Calderwood DA, Shattil SJ, Ginsberg MH. Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling. J Biol Chem. 2000;275(30):22607-22610.
11. Hulleman E, Boonstra J. Regulation of G1 phase progression by growth factors and the extracellular matrix. Cell Mol Life Sci. 2001;58(1):80-93.
12. Assoian RK, Schwartz MA. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev. 2001;11(1):48-53.
13. Kawano K, Kantak SS, Murai M, Yao CC, Kramer RH. Integrin α3/β1 engagement disrupts intercellular adhesion. Exp Cell Res. 2001;262(2):180-196.
14. Perlino E, Lovecchio M, Vacca RA, et al. Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma. Am J Pathol. 2000;157(5):1727-1734.
15. Bonaccorsi L, Carloni V, Muratori M, et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology. 2000;141(9):3172-3182.
16. Vihinen P, Nikkola J, Vlaykova T, et al. Prognostic value of beta1 integrin expression in metastatic melanoma. Melanoma Res. 2000;10(3):243-251.
17. Erdreich-Epstein A, Shimada H, Groshen S, et al. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000;60(3):712-721.
18. Mengarelli A, Zarcone D, Caruso R, et al. Adhesion molecule expression, clinical features and therapy outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2001;40(5-6):625-630.
19. Jayne DG, Heath RM, Dewhurst O, Scott N, Guillou PJ. Extracellular matrix proteins and chemoradiotherapy: α5β1 integrin as a predictive marker in rectal cancer. Eur J Surg Oncol. 2002;28(1):30-36.
20. Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative nonsmall cell lung cancer. Clin Cancer Res. 2000;6(1):96-101.
21. Yuan ST, Hu XQ, Lu JP, KeiKi H, Zhai WR, Zhang YE. Changes of integrin expression in rat hepatocarcinogenesis induced by 3′-Me-DAB. World J Gastroenterol. 2000;6(2):231-233.
22. Nishimori H, Yasoshima T, Hata F, et al. A novel nude mouse model of liver metastasis and peritoneal dissemination from the same human pancreatic cancer line. Pancreas. 2002;24(3):242-250.
23. Ishii Y, Ochiai A, Yamada T, et al. Integrin α6β4 as a suppressor and a predictive marker for peritoneal dissemination in human gastric cancer. Gastroenterology. 2000;118(3):497-506.
24. Ahmed N, Pansino F, Baker M, Rice G, Quinn M. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem. 2002;84(4):675-686.
25. Zhang GJ, Crist SA, McKerrow AK, Xu Y, Ladehoff DC, See WA. Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the α5β1 fibronectin receptor. J Urol. 2000;163(5):1553-1559.
26. Takechi T, Koizumi K, Tsujimoto H, Fukushima M. Screening of differentially expressed genes in 5-fluorouracil-resistant human gastrointestinal tumor cells. Jpn J Cancer Res. 2001;92(6):696-703.
27. Appierto V, Cavadini E, Pergolizzi R, et al. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br J Cancer. 2001;84(11):1528-1534.
28. Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L, Clynes M. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multi-drug resistance, integrin expression and in vitro invasiveness. Eur J Cancer. 2001;37(8):1041-1052.
29. Hikawa T, Mori T, Abe T, Hori S. The ability in adhesion and invasion of drug-resistant human glioma cells. J Exp Clin Cancer Res. 2000;19(3):357-362.
30. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61(5):1781-1785.
31. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42(2):326-336.
32. Davison E, Kirby I, Whitehouse J, Hart I, Marshall JF, Santis G. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be modulated by changes in beta1 integrin function. J Gene Med. 2001;3(6):550-559.
33. van Beusechem VW, Grill J, Mastenbroek DC, et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol. 2002;76(6):2753-2762.
34. Wesseling JG, Bosma PJ, Krasnykh V, et al. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 2001;8(13):969-976.
35. Grill J, van Beusechem VW, Van Der Valk P, et al. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res. 2001;7(3):641-650.
36. Bruning A, Kohler T, Quist S, et al. Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Hum Gene Ther. 2001;12(4):391-399.
37. Li E, Brown SL, Von Seggern DJ, Brown GB, Nemerow GR. Signaling antibodies complexed with adenovirus circumvent CAR and integrin interactions and improve gene delivery. Gene Ther. 2000;7(18):1593-1599.
38. Hemminki A, Belousova N, Zinn KR, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther. 2001;4(3):223-231.
39. Fujiwara H, Hamaoka T. Coordination of chemokine and adhesion systems in intratumoral T cell migration responsible for the induction of tumor regression. Int Immunopharmacol. 2001;1(4):613-623.
40. Mazzolini G, Narvaiza I, Bustos M, et al. Alpha(v)beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment. Mol Ther. 2001;3(5 part 1):665-672.
41. Zhang GJ, Crist SA, McKerrow AK, Xu Y, Ladehoff DC, See WA. Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the α5β1 fibronectin receptor. J Urol. 2000;163(5): 1553-1559.
42. Wiedle G, Johnson-Leger C, Imhof BA. A chimeric cell adhesion molecule mediates homing of lymphocytes to vascularized tumors. Cancer Res. 1999;59(20):5255-5263.
43. Maxwell IH, Chapman JT, Scherrer LC, et al. Expansion of tropism of a feline parvovirus to target a human tumor cell line by display of an alpha(v) integrin binding peptide on the capsid. Gene Ther. 2001;8(4):324-331.
44. Aoki Y, Hosaka S, Kawa S, Kiyosawa K. Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif. Cancer Gene Ther. 2001;8(10):783-787.
45. Nahde T, Muller K, Fahr A, Muller R, Brusselbach S. Combined transductional and transcriptional targeting of melanoma cells by artificial virus-like particles. J Gene Med. 2001;3(4):353-361.
46. Chen Y, Xu X, Hong S, et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res. 2001;61(6):2434-2438.
47. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti - alpha(v)beta3 integrin agents. J Neurooncol. 2000;46(2):135-144.
48. Hallahan DE, Qu S, Geng L, et al. Radiation-mediated control of drug delivery. Am J Clin Oncol. 2001;24(5):473-480.
49. Gould RJ, Polokoff MA, Friedman PA, et al. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med. 1990;195(2):168-171.
50. Ritter MR, Zhou Q, Markland FS Jr. Contortrostatin, a homodimeric disintegrin, actively disrupts focal adhesion and cytoskeletal structure and inhibits cell motility through a novel mechanism. Cell Adhes Commun. 2001;8(2):71-86.
51. Cohen SA, Trikha M, Mascelli MA. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res. 2000;6(3):163-174.
52. Rust WL, Huff JL, Plopper GE. Screening assay for promigratory/antimigratory compounds. Anal Biochem. 2000;280(1):11-19.